Herpes Simplex Infections

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

H
HologicMA - Marlborough
1 program
Evaluation of the HSV 1 & 2 Assay in Specimens From Symptomatic SubjectsN/A1 trial
Active Trials
NCT02270099Completed839Est. Jun 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
HologicEvaluation of the HSV 1 & 2 Assay in Specimens From Symptomatic Subjects

Clinical Trials (1)

Total enrollment: 839 patients across 1 trials

NCT02270099HologicEvaluation of the HSV 1 & 2 Assay in Specimens From Symptomatic Subjects

Evaluation of the HSV 1 & 2 Assay in Specimens From Symptomatic Subjects

Start: Dec 2014Est. completion: Jun 2017839 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space